Brought to you by 
Verastem completes $20.1mm Series C round
16 Nov 2011
Executive Summary
Just prior to filing for its initial public offering, cancer drug discovery start-up Verastem Inc. raised $20.1mm through its Series C round. New investor Eastern Capital led with a $9mm contribution, and was joined by returning backers CHP (managed by Cardinal Partners), Longwood Founders Fund, MPM Bioventures, Bessemer Venture Partners, Advanced Technology Ventures, and 28 additional investors.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Verastem completes $20.1mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice